CJS Securities Initiates Coverage on Bioventus

Analysts set $14 price target, citing 'outperform' rating for medical device company

Mar. 27, 2026 at 2:12pm

Got story updates? Submit your updates here. ›

Equities research analysts at CJS Securities have initiated coverage on shares of Bioventus (NASDAQ:BVS), a global medical device company specializing in orthobiologic solutions. The firm set an "outperform" rating on the stock and a $14.00 price target, indicating a potential upside of 49.25% from the stock's previous close.

Why it matters

This coverage initiation by CJS Securities provides an independent, third-party assessment of Bioventus' business prospects and growth potential. As a leading medical device company in the orthobiologics space, Bioventus' performance is closely watched by investors and industry analysts.

The details

In their research note, CJS Securities cited Bioventus' portfolio of non-surgical therapies designed to address bone healing, osteoarthritis pain management, and soft tissue repair. The analysts specifically highlighted the company's flagship EXOGEN Ultrasound Bone Healing System, which utilizes low-intensity pulsed ultrasound technology to stimulate bone growth.

  • CJS Securities initiated coverage on Bioventus on Friday, March 27, 2026.

The players

Bioventus

A global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions.

CJS Securities

An equities research firm that has initiated coverage on Bioventus with an "outperform" rating and a $14.00 price target.

Got photos? Submit your photos here. ›

The takeaway

This coverage initiation by a respected research firm highlights the growth potential of Bioventus as a leading player in the orthobiologics market. Investors will be closely watching the company's performance and any further analyst commentary as it looks to capitalize on its innovative product portfolio.